Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05154994 · ClinicalTrials.gov registry record · Phase 1

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma

A Phase 1 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma, sponsored by University of Utah.

Active
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT05154994 is a Phase 1 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 9 participants, below the 130-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05154994, a Phase 1 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma, is active but no longer recruiting, sponsored by University of Utah.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of belinostat when given together with durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nodes (locally advanced). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Belinostat is a potential anti-cancer drug, known as a histone deacetylase (HDAC) inhibitor, which means that belinostat stops the activity of HDAC enzymes (an enzyme is a protein that in small amounts can speed up a biological reaction). HDAC enzymes play an important role in cell growth and cell death. Giving durvalumab and belinostat may improve the body's ability to fight cancer.

Conditions Studied

Metastatic Urothelial Carcinoma Locally Advanced Urothelial Carcinoma Unresectable Urothelial Carcinoma Infiltrating Urothelial Carcinoma, Sarcomatoid Variant

Interventions

  • BIOLOGICAL Durvalumab
  • DRUG Belinostat

Study Locations (1)

Utah

  • Huntsman Cancer Institute/University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2022-01-14
Est. Completion 2027-11-30
Phase Phase 1

Sponsor

University of Utah

818 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05154994

The ClinicalTrials.gov registry entry for NCT05154994 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (93% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Metastatic Urothelial Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.

NCT05154994 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.

Frequently Asked Questions

What is clinical trial NCT05154994 about?

NCT05154994 is a clinical study titled "Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma". This phase I trial studies the side effects and best dose of belinostat when given together with durvalumab in treating patients with urothelial cancer that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and has spread to nearby tissue or lymph nod...

What is the current status of trial NCT05154994?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2022-01-14. Estimated completion is 2027-11-30.

What conditions does trial NCT05154994 study?

This clinical trial studies the following conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Infiltrating Urothelial Carcinoma, Sarcomatoid Variant.

What interventions are being tested in trial NCT05154994?

The interventions under investigation include: Durvalumab (BIOLOGICAL), Belinostat (DRUG).

Who is sponsoring clinical trial NCT05154994?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05154994 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Urothelial Carcinoma

All registered trials for this condition

Locally Advanced Urothelial Carcinoma

All registered trials for this condition

Utah

All trials with a study site in Utah

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.